Further, using the same xenograft model, it was shown that the ABL ATP-site kinase inhibitors, imatinib or nilotinib, and the ABL allosteric inhibitor GNF-5, reduced invadopodia-mediated breast cancer cell metastasis by decreasing matrix metalloproteinase activity, cell invasion, and subsequent metastasis to the lungs [9]. This evidence concerns the gene ABL1 and breast carcinoma.